Emerging treatments

Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma(Kmm150). Jung SH et al. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30019-3. doi: 10.1016/j.bbmt.2018.01.004. [Epub ahead of print]. The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma. Comeau JM et al. Am J Health Syst Pharm. 2018…

Diagnostic techniques and prognostic indicators

Prognostic Value of IL-10 and Its Relationship with Disease Stage in Iranian Patients with Multiple Myeloma. Shekarriz R et al.Asian Pac J Cancer Prev. 2018 Jan 27;19(1):27-32. Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient: Preliminary Results From a Single-center Study. Wu C et al. Acad Radiol. 2018 Jan 16. pii: S1076-6332(17)30518-4. doi: 10.1016/j.acra.2017.12.008.…

Current treatments

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. Dhakal B et al. JAMA Oncol. 2018 Jan 4. doi: 10.1001/jamaoncol.2017.4600. [Epub ahead of print]. Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Gertz MA et al. Mayo Clin Proc. 2018 Jan;93(1):56-58. doi: 10.1016/j.mayocp.2017.09.012. Prolonged survival after second autologous transplantation and lenalidomide maintenance…

Complications of myeloma and its treatments

Hemostatic Abnormalities in Multiple Myeloma Patients. Gogia A et al. Asian Pac J Cancer Prev. 2018 Jan 27;19(1):127-130. Incidence of Second Primary Malignancies after Autologous Transplantion for Multiple Myeloma in the Era of Novel Agents. Sahebi F et al. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30021-1. doi: 10.1016/j.bbmt.2018.01.006. [Epub ahead of print]. Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem…

Biology and genetics

Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics. Kamande JW et al. Integr Biol (Camb). 2018 Jan 26. doi: 10.1039/c7ib00183e. [Epub ahead of print]. Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib…

Supportive treatments

Mobilization of Hematopoietic Progenitor Cells with Standard or Reduced Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients. a Randomized Prospective Single Center Phase II Study. Samaras P et al. Biol Blood Marrow Transplant. 2017 Dec 12. pii: S1083-8791(17)31679-8. doi: 10.1016/j.bbmt.2017.12.775. [Epub ahead of print]. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.…

Related conditions

Pattern of care and impact of prognostic factors on the outcome of head and neck extramedullary plasmacytoma: a systematic review and individual patient data analysis of 315 cases. Venkatesulu B et al. Eur Arch Otorhinolaryngol. 2017 Dec 9. doi: 10.1007/s00405-017-4817-z. [Epub ahead of print]. Case Report: Treatment of Light Chain Amyloidosis with Daratumumab Monotherapy in Two Patients. Gran…

General

Falls in Older Adults with Multiple Myeloma. Wildes TM et al. Eur J Haematol. 2017 Dec 14. doi: 10.1111/ejh.13009. [Epub ahead of print]. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations From the Organizing Committee. Holstein SA et al. Biol Blood Marrow Transplant. 2017 Dec 11. pii: S1083-8791(17)31678-6. doi: 10.1016/j.bbmt.2017.12.774. [Epub ahead of print]. Multiple Myeloma and Bone:…

Emerging treatments

A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma. Ri M et al. Intern Med. 2017 Dec 8. doi: 10.2169/internalmedicine.9567-17. [Epub ahead of print]. Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma. Meyers DE et al. Blood Cancer J. 2017 Dec 5;7(12):640. doi: 10.1038/s41408-017-0020-0.…

Diagnostic techniques and prognostic indicators

Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient. Sachpekidis C et al. Diagnostics (Basel). 2017 Dec 15;7(4). pii: E61. doi: 10.3390/diagnostics7040061. Predictive value of 18 F-FDG PET/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma. Tu…